A Live-Attenuated HSV-2 ICP0-Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine

William P. Halford, Ringo Püschel, Edward Gershburg, Andrew Wilber, Svetlana Gershburg, Brandon Rakowsk | March 11, 2011

Antibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2

William P. Halford, Joshua Geltz, Ronald J. Messer, Kim J. Hasenkru | December 15, 2015

A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity

Derek J. Royer, Hem R. Gurung, Jeremy K. Jinkins, Joshua Geltz, Jennifer L. Wu, William P. Halford, Daniel J.J. Carr | June, 2016

Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice

Derek J. Royer, Meghan M. Carr, Anna J. Chucair-Elliott, William P. Halford, Daniel J.J. Carr | April, 2017

The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa

Derek J. Royer, Mehan M. Carr, Hem R. Gurung, William P. Halford and Daniel J. J. Carr | July 31, 2017

Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection.

Derek J. Royer, Joshua F. Hendrix, Chelsea M. Larabee, Alaina M. Reagan, Virginie H. Sjoelund, Danielle M. Robertson and Daniel J.J. Carr | January, 2019

The rational design of vaccines

Vincent W. Bramwell, Yvonne Perrie | November 15, 2005